PMC:7076992 / 3601-3826 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T10","span":{"begin":131,"end":136},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T20","span":{"begin":57,"end":65},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T22","span":{"begin":131,"end":136},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T23","span":{"begin":142,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T24","span":{"begin":196,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T18","span":{"begin":158,"end":166},"obj":"Chemical"}],"attributes":[{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":185,"end":206},"obj":"http://purl.obolibrary.org/obo/GO_0006956"},{"id":"T3","span":{"begin":211,"end":223},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T28","span":{"begin":0,"end":225},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"83","span":{"begin":57,"end":67},"obj":"Species"}],"attributes":[{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}